

Table of Contents

Volume 1

CHAPTER 1. OVERVIEW OF DRUG USE, TESTING, AND LEGALIZATION

I. SUBSTANCE ABUSE IN SOCIETY—EXTENT AND COSTS

- § 1:1 Substance abuse in the United States
- § 1:2 —Adolescents
- § 1:3 —Illicit Drug Use
- § 1:4 —Alcohol Use
- § 1:5 —Disorder
- § 1:6 —Treatment
- § 1:7 —Need for and barriers to substance use treatment
- § 1:8 —Co-occurring substance use disorders and mental health issues
- § 1:9 Cost of substance abuse within the workplace
- § 1:10 Cost of substance abuse—International

II. SUBSTANCE ABUSE IN THE WORKPLACE— EXTENT AND COSTS

- § 1:11 Drug and alcohol use in the workplace
- § 1:12 Drug test positivity rates, and drug test cheating
- § 1:13 Drug and alcohol use in the workplace—Industries/
workplace settings
- § 1:14 —Small businesses
- § 1:15 —Employer health care costs
- § 1:16 —Age of worker
- § 1:17 —International

III. DRUG-FREE WORKPLACE FACTS

A. THE NATURE OF MARIJUANA

- § 1:18 Introduction to marijuana facts
- § 1:19 Nature of marijuana/cannabis— Δ^9 -Tetrahydrocannabinol (THC)
- § 1:20 Marijuana use on the rise among adults and children and is causing severe damage

- § 1:21 Marijuana is addictive
- § 1:22 Rise in THC levels in marijuana
- § 1:23 How marijuana is used
- § 1:24 Marijuana concentrates, extracts and edibles
- § 1:25 —THC extraction process
- § 1:26 —Effects of concentrates on users
- § 1:27 —How are concentrates abused?
- § 1:28 —Concentrates compared to smoked marijuana
- § 1:29 Marijuana use and the Gateway effect
- § 1:30 Marijuana overdoses
- § 1:31 Science on marijuana and pain

B. CONCERNS FOR EMPLOYERS

- § 1:32 Effects of marijuana use—Pharmacological, psychological, mental, physiological, and side effects and why employers should still test for marijuana—The DOT opinion
- § 1:33 —Duration of effects
- § 1:34 —Lifetime effects
- § 1:35 Marijuana and impact on the brain
- § 1:36 Marijuana and mental health—Concerns for employers
- § 1:37 Marijuana and employer concerns about driving, job performance and safety
- § 1:38 Marijuana urine test results, pharmacokinetics and interpretation of blood concentrations
- § 1:39 Marijuana and other drug interactions
- § 1:40 Workplace and other violence and marijuana
- § 1:41 CBD (cannabidiol) safety, drug testing, employee health and work performance
- § 1:42 Employees who test positive for THC but claim they were only using CBD
- § 1:43 Coronavirus and marijuana use
- § 1:44 Effects of Marijuana on Driving and Operating Machinery
- § 1:45 Recreational marijuana sales and workplace injuries
- § 1:46 Second-hand marijuana smoke
- § 1:47 Hemp products and drug testing

C. HOW THE FEDERAL GOVERNMENT VIEWS MARIJUANA

- § 1:48 The federal classification of marijuana
- § 1:49 Role of the Food and Drug Administration and marijuana
- § 1:50 Marijuana contamination and employees' health

IV. EFFECTIVENESS OF WORKPLACE DRUG AND ALCOHOL TESTING

- § 1:51 Detection by drug testing

TABLE OF CONTENTS

- § 1:52 Self reporting versus actual drug tests results
- § 1:53 Beliefs about testing
- § 1:54 Government studies of drug testing
- § 1:55 Department of Transportation Requirements

V. IMPACT OF LEGALIZATION OF DRUGS

A. TYPES OF LEGALIZATION

- § 1:56 Types of legalization

B. THE CONVENTIONS

- § 1:57 United Nations International Drug Control
Conventions and the International Narcotic Control
Board
- § 1:58 Position of International Narcotic Control Board
- § 1:59 —Legalization of non-medical use of drugs
- § 1:60 United Nations International Drug Control
Conventions and the International Narcotic Control
Board—Questions regarding implementation of drug
legalization
- § 1:61 —Violation by the United States

C. HISTORY AND CRIMES

- § 1:62 History of alcohol prohibition
- § 1:63 Strong penalties for drug use—Deterrent effect
- § 1:64 Sale of illicit drugs—Purchase related crimes
- § 1:65 Drug-related crime
- § 1:66 Mass marketing and drug profits
- § 1:67 Black market crime
- § 1:68 Tax revenue and legalization

D. DRUGGED DRIVING

- § 1:69 Drugged driving—Marijuana and other drugs
- § 1:70 —Effect of marijuana legalization

E. LEGALIZATION AND COMMERCIALIZATION

- § 1:71 Marijuana legalization and commercialization—
Negative impact
- § 1:72 —Known Harms of Marijuana Use
- § 1:73 —Impact on public health
- § 1:74 —Effect on the immune system
- § 1:75 —Addiction
- § 1:76 —Impact on Public Safety
- § 1:77 —Impact on productivity
- § 1:78 —Impact on Public Budgets

- § 1:79 —Economic Consequences
- § 1:80 —Increase in Healthcare Costs
- § 1:81 —Negative Impact on Youth
- § 1:82 —Criminal Justice Costs
- § 1:83 —Substantial Implementation Costs
- § 1:84 —Aggregate Burden Outweighs Benefit
- § 1:85 —Tax revenues
- § 1:86 —Overview and conclusion
- § 1:87 —Social, personal, and public health problems
- § 1:88 —Recent data

F. WORKPLACE TESTING AND NOTICE

- § 1:89 Workplace drug testing in the era of legal marijuana
- § 1:90 Arizona Chamber of Commerce policy brief—
Recreational Marijuana: Is the Case for Legalization
Going Up in Smoke?
- § 1:91 DOT recreational marijuana notice
- § 1:92 Websites regarding medical and recreational
marijuana

VI. MEDICAL MARIJUANA IN THE WORKPLACE

A. LAWS AND GUIDELINES

- § 1:93 Medical Marijuana in the Workplace—Passage of laws
- § 1:94 Employers' concerns
- § 1:95 Employer guidelines and current case law

B. FACTS ABOUT MEDICAL MARIJUANA

- § 1:96 Facts about medical marijuana—Overview
- § 1:97 —Crude marijuana
- § 1:98 —Crude marijuana is not a safe and effective
medicine
- § 1:99 —National medical organizations oppose medical
marijuana
- § 1:100 —Anecdotal reports not reliable scientific evidence.
- § 1:101 —Need for research
- § 1:102 —FDA approved cannabinoid medicines and drug
testing
- § 1:103 —Patient rights and doctor recommendations
- § 1:104 —Smoking marijuana
- § 1:105 —Protection against unsafe and ineffective drugs and
the role of the FDA
- § 1:106 —FDA statement regarding smoked marijuana as
medicine
- § 1:107 —Medical marijuana and children
- § 1:108 —Addiction

TABLE OF CONTENTS

- § 1:109 —Safety and side effects
- § 1:110 —Marijuana and the immune system
- § 1:111 —State medical marijuana laws
- § 1:112 —Overall plan regarding marijuana
- § 1:113 —Funding the medical marijuana movement
- § 1:114 —Law enforcement problem
- § 1:115 —Medical marijuana shops
- § 1:116 —No impediments to legitimate research.
- § 1:117 Who is really using marijuana under the guise of medicine?

C. DAMAGE AND EFFECTIVENESS

- § 1:118 Damage caused by medical marijuana
- § 1:119 Effectiveness of medical marijuana
- § 1:120 —Chemotherapy
- § 1:121 —HIV
- § 1:122 —Glaucoma
- § 1:123 —Spastic quadriplegia
- § 1:124 —Multiple sclerosis

D. EMPLOYER RESPONSIBILITIES

- § 1:125 Reasonable accommodation for medical marijuana users
- § 1:126 Positive drug testing for marijuana
- § 1:127 Workers compensation for medical marijuana users
- § 1:128 Wrongful discharge and medical marijuana
- § 1:129 “Unlawful” medical marijuana use under state law
- § 1:130 State-by-state review of the medical marijuana laws as they affect employment

VII. PHYSICIAN ROLE AND MEDICAL MARIJUANA

- § 1:131 Physician prescriptions for medical marijuana
- § 1:132 Medical malpractice and medical marijuana

VIII. THE CONTROLLED SUBSTANCES ACT (CSA), MEDICAL MARIJUANA, AND LEGALIZATION

- § 1:133 The Controlled Substances Act
- § 1:134 Conflict between federal law and state laws
- § 1:135 Is marijuana control a states’ rights issue?
- § 1:136 —Enforcement of the CSA
- § 1:137 —Marijuana is a Schedule I controlled substance
- § 1:138 Federal prosecution in medical marijuana states
- § 1:139 Violation of the CSA

- § 1:140 Property owners and landlords who violate the CSA
- § 1:141 Financiers and banks who violate the CSA
- § 1:142 Immunity of state employees from prosecution for violating the CSA
- § 1:143 Federal tax consequences of trafficking in marijuana
- § 1:144 Medical marijuana, the Controlled Substances Act and the Congressional Research Service opinion
- § 1:145 Legalization of marijuana and the Racketeer Influenced and Corrupt Organizations Act (RICO)
- § 1:146 The Controlled Substances Act—Department of Justice (DOJ) position
- § 1:147 FDA enforcement against marijuana manufacturers
- § 1:148 —Smoking devices
- § 1:149 —Marijuana vaporizers
- § 1:150 The role of the Food and Drug Administration and medical marijuana
- § 1:151 Marijuana industry contracts in contravention of public policy may be void and unenforceable under the CSA and state law

CHAPTER 2. PUBLIC EMPLOYEE DRUG AND ALCOHOL TESTING—CONSTITUTIONAL AND PROCEDURAL ISSUES

- § 2:1 Requirement of state action
- § 2:2 Alternatives to drug and alcohol testing
- § 2:3 —Background checks
- § 2:4 —Searches of employee property
- § 2:5 —Polygraphs
- § 2:6 —Electronic eavesdropping and undercover agents
- § 2:7 —Observations
- § 2:8 —Performance tests
- § 2:9 —The drug recognition process
- § 2:10 —Horizontal Gaze Nystagmus test
- § 2:11 Drug testing as reasonable search
- § 2:12 Supreme Court position on Fourth Amendment and employee drug testing—O'Connor v. Ortega
- § 2:13 —Skinner v. Railway Labor Executives' Association
- § 2:14 —National Treasury Employees Union v. Von Raab
- § 2:15 State constitutional issues
- § 2:16 Consent and refusal to test
- § 2:17 Due process in public employment drug testing
- § 2:18 —Right to a hearing and test accuracy
- § 2:19 —Substantive and due process
- § 2:20 —Notice
- § 2:21 —Opportunity to contest drug test results

TABLE OF CONTENTS

§ 2:22	Self-incrimination
§ 2:23	Exclusionary rule
§ 2:24	Property
§ 2:25	Liberty
§ 2:26	Equal protection
§ 2:27	Preemployment
§ 2:28	Probationary period testing
§ 2:29	Reasonable suspicion
§ 2:30	Arrests and reasonable suspicion for testing
§ 2:31	Random tests
§ 2:32	—Case law on random testing of federal designated positions
§ 2:33	Medical examinations
§ 2:34	Posttreatment
§ 2:35	School teachers and other school employees
§ 2:36	School bus drivers and mechanics
§ 2:37	Law enforcement personnel—Police, corrections, probation and parole
§ 2:38	Military drug testing
§ 2:39	Military personnel and marijuana and cannabidiol (CBD)
§ 2:40	Military drug testing—Civilian employees
§ 2:41	Drug-free federal workplace armed forces civilian personnel and involvement with marijuana growing or distributing
§ 2:42	Firefighters
§ 2:43	Transportation
§ 2:44	Safety and security sensitive public employees
§ 2:45	Questions to answer in designing a public employee drug/alcohol testing process and hearing process
§ 2:46	Drug and alcohol testing policy—Post-accident or incident
§ 2:47	Limitation of freedom of speech
§ 2:48	Zero tolerance policies
§ 2:49	Conduct of hearings, admissibility, quality and weight of evidence in public and private employment

CHAPTER 3. PRIVATE EMPLOYMENT AND COMMON LAW

I. TESTING, EXAMINATIONS, AND ISSUES

§ 3:1	Consent and refusal to test
§ 3:2	Preemployment
§ 3:3	Probationary period
§ 3:4	Reasonable suspicion testing
§ 3:5	Postaccident

- § 3:6 OSHA Rule on Reporting Workplace Injuries and Post-accident Drug Testing
- § 3:7 OSHA Rule on Reporting Workplace Injuries and Post-accident Drug Testing—Examples and interpretations
- § 3:8 OSHA Rule on Reporting Workplace Injuries and Post-accident Drug Testing—OSHA memorandum
- § 3:9 Random testing
- § 3:10 Medical examinations
- § 3:11 Post-treatment
- § 3:12 Federal preemption of employee state law claims
- § 3:13 Public policy issues

II. ISSUE OF TORTS

- § 3:14 Torts
- § 3:15 —Negligence
- § 3:16 —Negligent hiring or retention
- § 3:17 —Liability of employers for employee intoxication and for drunk and drugged driving
- § 3:18 Tort—Defamation
- § 3:19 Torts—Invasion of privacy—Intrusion
- § 3:20 —Unreasonable publicity and false light
- § 3:21 —Intentional or negligent infliction of emotional distress/outrageous conduct
- § 3:22 —False imprisonment
- § 3:23 —Wrongful discharge

III. STATE WORKER'S COMPENSATION

- § 3:24 State workers' compensation and drug and alcohol issues
- § 3:25 State by state review—Workers' compensation discounts—Compliance with state drug-free workplace programs
- § 3:26 State workers' compensation statutes and cases relating to substance abuse
- § 3:27 State workers' compensation statutes and cases—Alabama
- § 3:28 —Alaska
- § 3:29 —Arizona
- § 3:30 —Arkansas
- § 3:31 —California
- § 3:32 —Colorado
- § 3:33 —Connecticut
- § 3:34 —Delaware
- § 3:35 —District of Columbia
- § 3:36 —Florida
- § 3:37 —Georgia

TABLE OF CONTENTS

§ 3:38	—Hawaii
§ 3:39	—Idaho
§ 3:40	—Illinois
§ 3:41	—Indiana
§ 3:42	—Iowa
§ 3:43	—Kansas
§ 3:44	—Kentucky
§ 3:45	—Louisiana
§ 3:46	—Maine
§ 3:47	—Maryland
§ 3:48	—Massachusetts
§ 3:49	—Michigan
§ 3:50	—Minnesota
§ 3:51	—Mississippi
§ 3:52	—Missouri
§ 3:53	—Montana
§ 3:54	—Nebraska
§ 3:55	—Nevada
§ 3:56	—New Hampshire
§ 3:57	—New Jersey
§ 3:58	—New Mexico
§ 3:59	—New York
§ 3:60	—North Carolina
§ 3:61	—North Dakota
§ 3:62	—Ohio
§ 3:63	—Oklahoma
§ 3:64	—Oregon
§ 3:65	—Pennsylvania
§ 3:66	—Puerto Rico
§ 3:67	—Rhode Island
§ 3:68	—South Carolina
§ 3:69	—South Dakota
§ 3:70	—Tennessee
§ 3:71	—Texas
§ 3:72	—Utah
§ 3:73	—Vermont
§ 3:74	—Virginia
§ 3:75	—West Virginia
§ 3:76	—Wisconsin
§ 3:77	—Wyoming

IV. STATE WORKER'S UNEMPLOYMENT BENEFIT LAWS

§ 3:78	State unemployment benefit laws—Misconduct
§ 3:79	State unemployment benefit laws and case law
§ 3:80	—Alabama

DRUG TESTING LAW TECHNOLOGY AND PRACTICE

- § 3:81 —Alaska
- § 3:82 —Arizona
- § 3:83 —Arkansas
- § 3:84 —California
- § 3:85 —Colorado
- § 3:86 —Connecticut
- § 3:87 —Delaware
- § 3:88 —District of Columbia
- § 3:89 —Florida
- § 3:90 —Georgia
- § 3:91 State unemployment benefit laws and case law—
Hawaii *[Reserved]*
- § 3:92 —Idaho
- § 3:93 —Illinois
- § 3:94 —Indiana
- § 3:95 —Iowa
- § 3:96 —Kansas
- § 3:97 —Kentucky
- § 3:98 —Louisiana
- § 3:99 —Maine
- § 3:100 —Maryland
- § 3:101 —Massachusetts
- § 3:102 —Michigan
- § 3:103 —Minnesota
- § 3:104 —Mississippi
- § 3:105 —Missouri
- § 3:106 State unemployment benefit laws and case law—
Montana *[Reserved]*
- § 3:107 —Nebraska
- § 3:108 —Nevada
- § 3:109 —New Hampshire
- § 3:110 —New Jersey
- § 3:111 —New Mexico
- § 3:112 —New York
- § 3:113 —North Carolina
- § 3:114 —North Dakota
- § 3:115 —Ohio
- § 3:116 —Oklahoma
- § 3:117 —Oregon
- § 3:118 —Pennsylvania
- § 3:119 State unemployment benefit laws and case law—Puerto
Rico *[Reserved]*
- § 3:120 State unemployment benefit laws and case law—Rhode
Island *[Reserved]*
- § 3:121 —South Carolina
- § 3:122 State unemployment benefit laws and case law—South
Dakota *[Reserved]*

TABLE OF CONTENTS

- § 3:123 —Tennessee
- § 3:124 —Texas
- § 3:125 —Utah
- § 3:126 State unemployment benefit laws and case law—
Vermont [*Reserved*]
- § 3:127 —Virginia
- § 3:128 —Washington
- § 3:129 —West Virginia
- § 3:130 —Wisconsin
- § 3:131 —Wyoming
- § 3:132 —Refusal to test

CHAPTER 3A. LABOR LAW AND DISCRIMINATION LAW

I. ISSUE OF CONTRACTS

- § 3A:1 Contracts
- § 3A:2 —policies as contracts
- § 3A:3 —Laboratories, MROs, and third party
administrators
- § 3A:4 Labor law and drug and alcohol testing
- § 3A:5 Drug testing and unfair labor practices by employers
- § 3A:6 Labor law—Collective bargaining
- § 3A:7 —Collective bargaining not required
- § 3A:8 —Collective bargaining required
- § 3A:9 —Unilateral implementation versus negotiated
implementation of drug testing
- § 3A:10 —Arbitration
- § 3A:11 State laws regarding collective bargaining and drug
testing
- § 3A:12 Preparing for collective bargaining over drug and
alcohol testing

II. ISSUE OF DISCRIMINATION

- § 3A:13 Discrimination
- § 3A:14 Racial discrimination
- § 3A:15 ADA and drug-free workplaces
- § 3A:16 Summary of ADA protections—Exemptions for drug
addiction or use
- § 3A:17 ADA and past drug addiction
- § 3A:18 ADA and current illegal or legal use of drugs
- § 3A:19 ADA Protection—Enrollment in treatment program
- § 3A:20 ADA and alcohol use
- § 3A:21 ADA and legal use of drugs
- § 3A:22 ADA and reasonable accommodation

- § 3A:23 ADA and direct threat posed by substance abuse
- § 3A:24 ADA and employ rights and responsibilities
- § 3A:25 Pre-employment and medical examinations of applicants and employees
- § 3A:26 ADA and employment drug and alcohol testing
- § 3A:27 ADA and confidentiality
- § 3A:28 Other laws and regulations
- § 3A:29 Discrimination—Religion involvement
- § 3A:30 —Union involvement or lack of it

III. FAIR CREDIT REPORTING ACT

- § 3A:31 Drug testing and the Fair Credit Reporting Act

IV. FEDERAL FAMILY AND MEDICAL LEAVE ACT

- § 3A:32 Federal Family and Medical Leave Act, substance abuse, and drug testing

V. STATE FAMILY AND MEDICAL LEAVE LAWS

- § 3A:33 State family and medical leave laws—Treatments for substance abuse
- § 3A:34 Native americans tribal codes

CHAPTER 4. FEDERAL AND STATE TESTING LAWS

- § 4:1 State drug and alcohol testing laws for the workplace
- § 4:2 Federal laws and regulations

I. STATE DRUG-FREE WORKPLACE LAWS

- § 4:3 Alabama
- § 4:4 Alaska
- § 4:5 Arizona
- § 4:6 Arkansas
- § 4:7 California
- § 4:8 Colorado
- § 4:9 Connecticut
- § 4:10 Delaware
- § 4:11 District of Columbia
- § 4:12 Florida
- § 4:13 Georgia
- § 4:14 Hawaii
- § 4:15 Idaho
- § 4:16 Illinois
- § 4:17 Indiana
- § 4:18 Iowa

TABLE OF CONTENTS

§ 4:19	Kansas
§ 4:20	Kentucky
§ 4:21	Louisiana
§ 4:22	Maine
§ 4:23	Maryland
§ 4:24	Massachusetts
§ 4:25	Michigan
§ 4:26	Minnesota
§ 4:27	Mississippi
§ 4:28	Missouri
§ 4:29	Montana
§ 4:30	Nebraska
§ 4:31	Nevada
§ 4:32	New Hampshire
§ 4:33	New Jersey
§ 4:34	New Mexico
§ 4:35	New York
§ 4:36	North Carolina
§ 4:37	North Dakota
§ 4:38	Ohio
§ 4:39	Oklahoma
§ 4:40	Oregon
§ 4:41	Pennsylvania
§ 4:42	Puerto Rico
§ 4:43	Rhode Island
§ 4:44	South Carolina
§ 4:45	South Dakota
§ 4:46	Tennessee
§ 4:47	Texas
§ 4:48	Utah
§ 4:49	Vermont
§ 4:50	Virginia
§ 4:51	Virgin Islands
§ 4:52	Washington
§ 4:53	West Virginia
§ 4:54	Wisconsin
§ 4:55	Wyoming
§ 4:56	Model state drug-testing acts
§ 4:57	Drug-test fraud and adulteration laws—Federal

II. HORIZONTAL GAZE NYSTAGMUS TEST

§ 4:58	Horizontal Gaze Nystagmus test—In general
--------	---

III. DRUG RECOGNITION EXPERTS

§ 4:59	Drug recognition experts (DRE)—In general
--------	---

- § 4:60 The comprehensive New Jersey Supreme Court special master's final report on drug recognition experts
- § 4:61 Workplace impairment recognition experts (WIREs)

IV. DRUG-FREE WORKPLACE ACT OF 1988

- § 4:62 The Drug-Free Workplace Act for federal contractors and federal grantees
- § 4:63 Drug-Free Workplace Act

V. EXECUTIVE ORDER AND GUIDELINES—DRUG-FREE FEDERAL WORKPLACE

- § 4:64 Executive order for drug-free federal workplace
- § 4:65 —Procedures
- § 4:66 —Personnel actions
- § 4:67 Mandatory guidelines for federal workplace drug-testing programs
- § 4:68 A glossary of federal drug testing terms
- § 4:69 2023 Urine testing guidelines—Summary of major changes to 2017 guidelines
- § 4:70 2023 oral fluid guidelines—Summary of major changes to 2019 oral fluid guidelines
- § 4:71 HHS proposal—Revise drug testing procedures for urine testing
- § 4:72 New oral fluid guidelines for federal workplace drug testing programs
- § 4:73 HHS proposal—Use of hair testing for federal workplace drug testing
- § 4:74 Guidance for selection of testing designated positions
- § 4:75 Prescription drug abuse epidemic
- § 4:76 SAMHSA fact sheets on preventing prescription abuse in the workplace

VI. ALCOHOL AND DRUG-TESTING RULES FOR DEPARTMENT OF TRANSPORTATION

- § 4:77 Federal Department of Transportation alcohol and drug-testing rules
- § 4:78 Department of Transportation revisions to rules
- § 4:79 DOT notices about rule revisions
- § 4:80 Protections for Maintenance of Way Workers—Expansion of Drug and Alcohol Testing
- § 4:81 Significant vulnerabilities in DOT's drug-testing program
- § 4:82 DOT's management information system
- § 4:83 DOT questions and answers
- § 4:84 2023 Department of Transportation (DOT) random drug and alcohol testing rates

TABLE OF CONTENTS

§ 4:85	Do the FTA regulations apply?—Taxis
§ 4:86	—Ubers, Lyfts, and Ride-Sourcing
§ 4:87	DOT public interest exclusions (PIE)
§ 4:88	DOT rules and over-the-counter and prescription medicines
§ 4:89	HIPAA and DOT requirements
§ 4:90	FTA policy and procedures
§ 4:91	—Undercover collection site inspections
§ 4:92	DOT and FTA—Definition of “immediately”
§ 4:93	Failure to print confirmation tests
§ 4:94	Standardized information for collectors
§ 4:95	Qualification requirements for service agents
§ 4:96	File management and compliance
§ 4:97	Previous employers check for safety-sensitive functions
§ 4:98	Return-to-duty tests and redundant testing
§ 4:99	Revision of the federal drug testing custody and control form (CCF)
§ 4:100	Guidance for using the 2020 federal custody and control form (CCF) for urine specimens
§ 4:101	Information provided for positive drug/alcohol test or refusal to test
§ 4:102	Safety—Sensitive functions
§ 4:103	Safeguards to prevent tampering
§ 4:104	Batch testing of employees
§ 4:105	Records retention
§ 4:106	Use of law enforcement officers as breath alcohol technicians
§ 4:107	Delay/failure to conduct post-accident test
§ 4:108	Release of information on covered employee
§ 4:109	MRO information on federal forms
§ 4:110	Temperature of the specimen
§ 4:111	Frequent procedural errors performed by collectors
§ 4:112	Shy bladder scenario
§ 4:113	Calibration checks and documentation
§ 4:114	Instructions on back of custody and control form
§ 4:115	What DOT employers need to know about monitoring collection sites
§ 4:116	Reclassifying DOT tests as non-DOT tests
§ 4:117	Substance Abuse Professionals as gatekeepers
§ 4:118	Contractors under the FTA regulations
§ 4:119	Guidance for employees on transportation drug testing
§ 4:120	Commercial driver’s license drug and alcohol clearinghouse
§ 4:121	DOT drug testing: Part 40—Employee notice of testing for four semi-synthetic opioids

DRUG TESTING LAW TECHNOLOGY AND PRACTICE

- § 4:122 Video cameras and reasonable suspicion determinations for drug/alcohol test
- § 4:123 Tracking post-accident testing delays
- § 4:124 Non-DOT follow-up tests
- § 4:125 Employees must relinquish firearms at collection-site
- § 4:126 Evidential breath testing devices and manual mode
- § 4:127 Negative-dilute tests
- § 4:128 Policies and the term substance abuse professional
- § 4:129 Random rosters accuracy counts
- § 4:130 Preferred delivery of communication for positive drug test results
- § 4:131 Substance abuse professionals and compliant referral practice
- § 4:132 Removal of employee following a post-accident or reasonable suspicion occurrence
- § 4:133 DOT and DNA testing
- § 4:134 2016 drug and alcohol MIS results
- § 4:135 Responding to a 40.25 request for testing information
- § 4:136 The collector's role
- § 4:137 2016 Drug and alcohol MIS results
- § 4:138 Alcohol results less than 0.04 are not DOT violations
- § 4:139 Timely reasonable suspicion testing
- § 4:140 Employer oversight of MROs
- § 4:141 Pre-employment test refusals
- § 4:142 C/TPA information required on annual MIS submissions
- § 4:143 Top 5 audit findings
- § 4:144 Collector errors & affidavits
- § 4:145 No "expiration" on return-to-duty requirements
- § 4:146 Using mobile collection sites
- § 4:147 Who should be trained to make reasonable suspicion determinations
- § 4:148 Reasonable suspicion training
- § 4:149 Clarification: an employee who consumes alcohol while on-call has not violated a FTA prohibition
- § 4:150 Reviewing SAP letters & testing plans
- § 4:151 After hours testing
- § 4:152 Use a mobile collector
- § 4:153 Spot-checking your consortium/TPA
- § 4:154 Department of Transportation notice about the use of cannabidiol (CBD) for safety-sensitive employees who are subject to drug testing
- § 4:155 DOT Office of Drug and Alcohol Policy and Compliance Notice Regarding Hemp and CBD
- § 4:156 Frequently asked questions from FTA grantees regarding COVID-19 and FTA drug and alcohol testing requirements

TABLE OF CONTENTS

§ 4:157	Federal Motor Carrier Safety Administration Notice of Enforcement Discretion Determination: Random Controlled Substance and Alcohol Testing in Response to COVID-19
§ 4:158	DOT COVID-19 Drug & Alcohol Testing Statement of Enforcement Discretion for Substance Abuse Professionals and Service Agents
§ 4:159	DOT Coronavirus Disease 2019 (COVID-19) Guidance
§ 4:160	Completely discounting an operator's performance after a non-fatal accident
§ 4:161	Correcting errors on a custody and control form
§ 4:162	Employees who are randomly selected for both drug and alcohol tests
§ 4:163	MROs and "shy bladder" cases
§ 4:164	Pre-employment testing after an absence of 90 days
§ 4:165	Post-accident testing for mechanics under FTA rules
§ 4:166	Revenue vehicle operators vs. non-revenue vehicle operators with a CDL
§ 4:167	Custody and control form and employee ID numbers
§ 4:168	FTA follow-up alcohol test timing
§ 4:169	Late night and off-hours random testing notifications
§ 4:170	SAP referral required for pre-employment positives and refusals
§ 4:171	Custody and control form (CCF) errors and the federal motor carrier safety administration's (FMCSA) clearinghouse
§ 4:172	The 60-minute training must cover only effects and consequences of drug use
§ 4:173	Employer requirements when the MRO is unable to contact the employee
§ 4:174	Access to FTA drug and alcohol testing records
§ 4:175	Post-accident testing: FTA vs. FMCSA
§ 4:176	Step 3 of the federal alcohol testing form (atf) and common errors
§ 4:177	Flaws in alcohol testing when using an EBT
§ 4:178	Leftover urine from a dot drug test may not be used for non-dot testing
§ 4:179	Substance abuse professional (SAP) referrals for education and treatment
§ 4:180	Revenue vehicle control/dispatch is not a "catch-all" employee category
§ 4:181	Direct observation criteria under DOT rules
§ 4:182	Discovery of drug paraphernalia is not cause for reasonable suspicion testing
§ 4:183	FTA accidents and vehicle operation and testing
§ 4:184	DOT employers must ask applicants about pre-employment test failures and refusals
§ 4:185	How to prepare for an FTA or DOT audit

DRUG TESTING LAW TECHNOLOGY AND PRACTICE

- § 4:186 Shy lung in alcohol testing
- § 4:187 FTA and dot required choices and company options
and company policies
- § 4:188 FMCSA COVID-19 pre-employment testing guidance
- § 4:189 Data from the annual drug and alcohol management
information system (DAMIS) and FTA
- § 4:190 Evidentiary breath testing devices and daylight
saving time
- § 4:191 DOT management information system (MIS)
frequently asked questions
- § 4:192 Cancelled drug tests
- § 4:193 Third party administrators must meet DOT
requirements
- § 4:194 Pre-employment alcohol tests
- § 4:195 FTA testing other safety-sensitive employees after an
accident
- § 4:196 Marijuana use dominates positive drug testing rates
of commercial drivers
- § 4:197 Notice for federal drug testing collection sites and
CDL employers
- § 4:198 Procedures for transportation workplace drug and
alcohol testing programs: Addition of oral fluid
specimen testing for drugs
- § 4:199 List of organizations that obtain recognition for the
SAP credential for their members
- § 4:200 eCCF notice: urine specimen collectors
- § 4:201 Drug and alcohol Management Information System
(MIS) data must be in before safety sensitive
contracts terminate
- § 4:202 What DOT managers are really safety-sensitive?
- § 4:203 Employees who test positive for a controlled
substance may no longer possess firearms under
federal law
- § 4:204 The transit industry drug and alcohol positive rate
remains high
- § 4:205 Former Employees with Violations
- § 4:206 Non-contact responsibilities for Designated Employer
Representatives (DERs)
- § 4:207 DOT prohibitions and state drug decriminalization
- § 4:208 Software generated random test dates and times
- § 4:209 Saliva specimens and confirmation alcohol tests
- § 4:210 DOT employer drug and alcohol policies
- § 4:211 Referrals to Substance Abuse Professionals (SAPs)
- § 4:212 Random testing excusals
- § 4:213 Towing and post-accident testing
- § 4:214 Alcohol tests below 0.04 is not a DOT violation
- § 4:215 All DOT testing records must be legible
- § 4:216 Previous employer checks

TABLE OF CONTENTS

§ 4:217	Employees covered by FTA and FMCSA
§ 4:218	Two tests for one event: which is the test of record?
§ 4:219	Laboratory summary reports
§ 4:220	Voluntary self-referral for help with substance use must be non-DOT
§ 4:221	Shy bladders and removal from safety-sensitive functions
§ 4:222	Employers may not adjust substance abuse professional testing plans
§ 4:223	Who should be listed as the certifying official on the annual drug and alcohol MIS report?
§ 4:224	Diabetes does not interfere with DOT alcohol testing
§ 4:225	Situation changes after post-accident determination
§ 4:226	State and local legislation prohibiting testing for marijuana does not apply to DOT employers
§ 4:227	Operators of revenue service vehicles on transit or private property are covered
§ 4:228	Previous employers must respond to requests for DOT testing information
§ 4:229	What happens when a collector finds items used to defraud a drug test?
§ 4:230	CBD may generate a THC positive
§ 4:231	Grantee's access to records when maintained by a Third-Party Administrator (TPA)
§ 4:232	Prescription medication cannot be verified solely using photographs
§ 4:233	Finding a qualified Substance Abuse Professional (SAP)
§ 4:234	What will the MRO report to the DER when there is a laboratory positive, adulterated, or substituted test result?
§ 4:235	Employers who operate seasonally must still meet minimum testing rates
§ 4:236	Common follow-up testing issues
§ 4:237	DOT tests are separate from and take priority over non-DOT tests
§ 4:238	Refusal exemptions for pre-employment tests
§ 4:239	Taxicab exception
§ 4:240	Unauthorized items left in the restroom
§ 4:241	Employer discretion when scheduling random tests
§ 4:242	If you receive FTA operating funds all safety-sensitive functions are covered
§ 4:243	Reclassifying drug and alcohol tests
§ 4:244	Designated Employer Representative (DER) must remove employee from safety-sensitive functions while awaiting, split specimen test results
§ 4:245	DOT oral fluids testing

VII. FOREIGN BASED OR NUCLEAR POWER EMPLOYEES

- § 4:246 Foreign-based employees
- § 4:247 Nuclear Power Employees
- § 4:248 Department of Defense interim rule on drug-free workplace

VIII. TESTING PRODUCTS AND LABORATORIES

- § 4:249 Alcohol screening devices
- § 4:250 Certified laboratories for federal drug-testing

IX. MEDICAL REVIEW OFFICERS

- § 4:251 Medical review officers—In general
- § 4:252 —Standard operating procedures and continuing education
- § 4:253 Medical review officer's responsibilities
- § 4:254 Medical review officers—Explanations proffered by employees regarding drug use
- § 4:255 —Drug test methods
- § 4:256 —Federal drug-testing custody and control form
- § 4:257 —Administrative review of the CCF
- § 4:258 —Technical review of single or primary specimen test result
- § 4:259 —Interview with the donor
- § 4:260 —Retest request and results
- § 4:261 —Report verified result to employer
- § 4:262 Medical review officers—The litigation package
- § 4:263 Medical review officers—Occupational and public safety
- § 4:264 —State initiatives and laws
- § 4:265 —Specific drug class issues—Amphetamines
- § 4:266 — —Cannabinoids (Marijuana)
- § 4:267 — —Cocaine
- § 4:268 — —Opioids
- § 4:269 Fentanyl and drug testing
- § 4:270 Fentanyl—Federal grantees may now use funds to purchase fentanyl test strips
- § 4:271 Medical review officers—Specific drug class issues—Phencyclidine (PCP)
- § 4:272 Medical review officers—Documentation and recordkeeping
- § 4:273 —Confidentiality
- § 4:274 —Blind quality control samples
- § 4:275 —Shy bladder
- § 4:276 —Testing for additional drugs

TABLE OF CONTENTS

- § 4:277 —Certification
- § 4:278 Safety concerns require medical review officers to report medical information
- § 4:279 The revised DOT medical examiner’s handbook and medical advisory criteria proposed regulatory guidance

X. JURISDICTION OF ON-SITE DRUG AND ALCOHOL TESTING

- § 4:280 Jurisdiction of the FDA—On-site drug and alcohol testing
- § 4:281 Best practices for DOT’s drug-testing program

XI. HIPAA PRIVACY RULE

- § 4:282 Privacy rules under HIPAA—Federal drug and alcohol testing and DOT
- § 4:283 Federal medical privacy rules under HIPAA—Impact of testing laws on foreign companies and nationals

XII. FEDERAL REQUIREMENT FOR STATE DWI LAWS

- § 4:284 Federal requirement for state DWI laws—In general

XIII. FEDERAL DEPARTMENT OF ENERGY—TESTING RULES AND GUIDELINES

- § 4:285 The federal Department of Energy—Rules and Guidelines
- § 4:286 Federal Clinical Laboratory Improvement Act

CHAPTER 5. TECHNICAL ISSUES

I. METHODOLOGY

- § 5:1 Drug testing methods
- § 5:2 Substances detected by federal drug tests
- § 5:3 Specimen reporting criteria
- § 5:4 Drug detection times
- § 5:5 Initial drug tests

II. ON-SITE DRUG TESTING

- § 5:6 On-site drug tests
- § 5:7 Admissibility and reliability of on-site drug tests
- § 5:8 Confirmation test methods
- § 5:9 Specimen validity tests
- § 5:10 Screening and confirmatory drug testing reliability—Court cases

III. ANALYSIS AND TESTING METHODS

- § 5:11 Blood, hair, saliva and sweat testing
- § 5:12 Hair analysis—Drug testing
- § 5:13 —Passive contamination and hair testing
- § 5:14 —Test bias
- § 5:15 —Current findings and hair testing
- § 5:16 —Current state of hair testing
- § 5:17 Oral fluid (saliva) analysis—Drug testing
- § 5:18 Federal agencies' use of saliva (oral fluids) testing
- § 5:19 Sweat—Drug testing
- § 5:20 Breath testing
- § 5:21 Sensitivity and cutoffs of drug tests
- § 5:22 False positive, negative results, and test inaccuracy
- § 5:23 Passive inhalation or accidental exposure

IV. LABORATORY

- § 5:24 Laboratory selection
- § 5:25 Laboratory quality assurance and quality control
- § 5:26 Fatal flaws in drug testing that may result in finding the test invalid

Volume 2

CHAPTER 6. HOW TO ESTABLISH A DRUG TESTING PROGRAM

I. DUE PROCESS

- § 6:1 Due process rights of employee
- § 6:2 Procedural due process
- § 6:3 Due process—Substantive due process
- § 6:4 Due Process—Notice of drug or alcohol testing
- § 6:5 —Opportunity to contest drug test results
- § 6:6 Innocent ingestion defense

II. POLICY FOR DRUG AND ALCOHOL TESTING

A. PLANNING AND DEVELOPMENT

- § 6:7 Program planning and philosophy
- § 6:8 Written policy development
- § 6:9 Implementation of written policy

B. STATEMENT AND CONSEQUENCES

- § 6:10 Policy statement

TABLE OF CONTENTS

§ 6:11	Consequences of policy violation
§ 6:12	—Last Chance Agreements and treatment options
C. CONFIDENTIALITY, ENFORCEABILITY AND COMMUNICATION	
§ 6:13	Employee confidentiality
§ 6:14	Communication of policy
§ 6:15	Enforcement of policy
§ 6:16	Model information sheet for employees
D. FTA SUBSTANCE ABUSE POLICY IMPLEMENTATION	
§ 6:17	FTA substance abuse policy implementation—Checklist
§ 6:18	—Covered Employees
E. MODEL LANGUAGE FOR DRUG FREE WORKPLACE POLICIES	
§ 6:19	Model language for drug free workplace policies—In general
§ 6:20	—Model Policy 1
§ 6:21	—Model Policy 2
§ 6:22	—Model Policy 3
§ 6:23	—Model Policy 4
§ 6:24	—Model Policy 5
III. SPECIMEN COLLECTION PROCESS	
A. SPECIMEN COLLECTION UNDER THE DEPARTMENT OF TRANSPORTATION (DOT)	
§ 6:25	Specimen collection under the DOT
B. DOT URINE SPECIMEN COLLECTION GUIDELINES	
§ 6:26	DOT Urine Specimen Collection Guidelines—In general
§ 6:27	Requirements to be a collector
§ 6:28	Collection site
§ 6:29	Collection supplies
§ 6:30	Federal Drug Testing Custody and Control Form (CCF)
§ 6:31	Employee identification
§ 6:32	Collection procedures
§ 6:33	Shy bladder procedures
§ 6:34	Directly observed collections
§ 6:35	Transgender observed collections

- § 6:36 Monitored collections
- § 6:37 Problem collections
- § 6:38 —Catheterization
- § 6:39 —External urine bag
- § 6:40 Temperature of specimen
- § 6:41 Volume of Specimen
- § 6:42 Adulteration or substitution of specimen
- § 6:43 Blind quality control samples
- § 6:44 Correcting collection problems
- § 6:45 Regulated and non-regulated employers
- § 6:46 DOT Guidelines Appendix A—Training Requirements for Collectors
- § 6:47 DOT Guidelines Appendix B—Collection Site Security and Integrity
- § 6:48 DOT Guidelines Appendix C—Standards for Urine Collection Kits
- § 6:49 DOT Guidelines Appendix D—Direct Observation Procedures
- § 6:50 DOT Guidelines—Questions and Answers
- § 6:51 DOT Guidelines Appendix F—Operating Administrations’ Rules on Collection
- § 6:52 Retention of specimens for litigation

C. EMPLOYEE SPECIMEN COLLECTION AND CHAIN OF CUSTODY

- § 6:53 Employee specimen collection checklist—Collection of blood
- § 6:54 Specimen collection and chain of custody—Private and public employment
- § 6:55 Chain of custody issues
- § 6:56 Employee’s failure to comply
- § 6:57 Adulteration of tests
- § 6:58 Prison disciplinary hearings

IV. MEDICAL REVIEW OFFICERS AND SUBSTANCE ABUSE PROFESSIONALS

- § 6:59 Medical review officers
- § 6:60 Substance abuse professionals
- § 6:61 —Qualifications
- § 6:62 —Duties of a SAP
- § 6:63 —Regulations governing SAPs

V. PRE-EMPLOYMENT DRUG TESTING

- § 6:64 Pre-employment drug testing—Example for implementation

TABLE OF CONTENTS

§ 6:65 —Checklist

VI. RANDOM AND REASONABLE TESTING

§ 6:66 Implementation of random testing

§ 6:67 Reasonable suspicion testing

§ 6:68 Reasonable suspicion checklist

VII. POST-ACCIDENT TESTING AND RETURN-TO-DUTY

§ 6:69 Post-accident testing process

§ 6:70 —Alcohol tests

§ 6:71 —Drug tests

§ 6:72 Post-accident policy checklist

§ 6:73 Return to duty testing checklist

§ 6:74 DOT follow-up testing checklist

VIII. DOCUMENTATION

§ 6:75 Documentation checklist for litigation

§ 6:76 Proper record keeping

§ 6:77 —Maintenance of records

§ 6:78 —Chain of custody documents

IX. DRUG AND ALCOHOL SERVICES

A. CONSORTIA AND SERVICES

§ 6:79 Consortia to provide drug and alcohol services

§ 6:80 Lower costs and savings

§ 6:81 Professionalism and expertise

§ 6:82 Reduced administrative burden

§ 6:83 Pragmatism

§ 6:84 Reduced liability

B. CONSORTIA AND DISADVANTAGES

§ 6:85 Disadvantages

§ 6:86 —Shared design

§ 6:87 —Reduced control

§ 6:88 —Financial considerations

C. TYPES OF CONSORTIA

§ 6:89 Types of consortia

§ 6:90 —Purchasing cooperatives

§ 6:91 —Separate entity

§ 6:92 —Managing partner

§ 6:93 —External management

D. CONSORTIUM CONTRACT

- § 6:94 Importance of consortium contract

X. ON-SITE DRUG AND ALCOHOL TESTING

- § 6:95 On-site drug and alcohol testing—In general
§ 6:96 —Legal and technical advantages
§ 6:97 —Specimen collection
§ 6:98 —Operator certification
§ 6:99 —Employee confrontations
§ 6:100 —Paruresis or shy bladder syndrome
§ 6:101 Unsuitable on-site specimens

XI. CHECKLIST FOR IMPLEMENTATION

- § 6:102 Checklist to determine implementation of testing program
§ 6:103 How to avoid legal problems

XII. “PRIVATE” SUBSTANCE ABUSE

- § 6:104 Off-duty or off-worksites substance abuse

XIII. TRAINING REGARDING COMPANY POLICY

- § 6:105 Employee training

XIV. EMPLOYEE ASSISTANCE PROGRAM (EAP)

- § 6:106 Employee Assistance Programs—Background
§ 6:107 Employee assistance programs—Implementation
§ 6:108 —Referral

XV. PROTECTIONS UNDER THE FAMILY AND MEDICAL LEAVE ACT

- § 6:109 The Family and Medical Leave Act—Substance abuse treatment of employees

XVI. CONFIDENTIALITY

A. CONFIDENTIALITY

- § 6:110 Confidentiality procedures
§ 6:111 42 C.F.R. Part 2, Confidentiality of substance use disorder patient records
§ 6:112 Confidentiality Procedures—Federal treatment confidentiality
§ 6:113 Confidentiality and qualified service organizations
§ 6:114 Confidentiality and HIPAA—Pre-employment

TABLE OF CONTENTS

- physicals, drug tests, or fitness-for-duty examinations
- § 6:115 Confidentiality—State laws
- § 6:116 —Employment privacy laws
- § 6:117 —Physician-patient privilege
- § 6:118 —State medical and laboratory records laws

B. DISCLOSURE OF MEDICAL INFORMATION

- § 6:119 Disclosure of employee medical information—
Company physicians
- § 6:120 —Contractual right to confidentiality
- § 6:121 —Laboratory reports to employers
- § 6:122 —Preemployment test reporting

C. CONFIDENTIALITY AND GUIDELINES

- § 6:123 Confidentiality of alcohol test records—Americans
with Disabilities Act
- § 6:124 Guidelines to confidentiality

XVII. LAST CHANCE AGREEMENTS

- § 6:125 Last chance agreements (LCA)

XVIII. ORGANIZATIONS THAT CAN HELP

- § 6:126 The National Drug & Alcohol Screening Association:
the voice of an industry - forms and guidelines

XIX. PROGRAM MONITORING CHECKLIST

- § 6:127 Drug Testing Program Monitoring—Checklist
- § 6:128 Guidelines for employers—Drug overdoses

CHAPTER 7. ALCOHOL TESTING IN DUI/ DWI CASES AND IN EMPLOYMENT CASES

I. ALCOHOL USE, POLICIES, AND LAWS

A. ALCOHOL USE AND IMPACT

- § 7:1 Alcohol use in the United States
- § 7:2 Alcohol use, alcohol abuse, and employment
- § 7:3 Impact of alcohol on human physiology
- § 7:4 Fatal crashes and fatalities involving alcohol-impaired
drivers

B. LIABILITY

- § 7:5 State DUI, Dram Shop, and Social Host Laws

- § 7:6 Liability of employers for employee intoxication

C. POLICIES AND ISSUES

- § 7:7 Zero tolerance policy and DOT rules
- § 7:8 Legal authority for alcohol testing
- § 7:9 Policy issues in consideration for employee alcohol testing
- § 7:10 Alcohol testing procedures for employers
- § 7:11 Presumptions in prosecution of intoxicated driving charge

II. FEDERAL DEPARTMENT OF TRANSPORTATION RULES FOR ALCOHOL TESTING

- § 7:12 Federal DOT rules for alcohol testing
- § 7:13 —Technicians who can conduct tests
- § 7:14 —Qualified testing site
- § 7:15 —Testing procedures
- § 7:16 —Procedures for the screening test
- § 7:17 —Use of a saliva or breath tube ASD
- § 7:18 —Procedures after a screening test result
- § 7:19 —First steps in an alcohol confirmation test
- § 7:20 —Conducting an alcohol confirmation test
- § 7:21 —After the alcohol confirmation test result
- § 7:22 —Refusal to take an alcohol test and the consequences
- § 7:23 —Insufficient saliva
- § 7:24 —Insufficient amount of breath
- § 7:25 —Problems that always cause cancellation
- § 7:26 —Problems that cause cancellation unless corrected
- § 7:27 —Process to correct problems
- § 7:28 —Effect of a cancelled alcohol test
- § 7:29 —Procedural problems not sufficient to cancel test
- § 7:30 —Alcohol tests other than saliva or breath

III. FEDERAL MOTOR CARRIER SAFETY ADMINISTRATION ALCOHOL TESTING PROCEDURES

- § 7:31 FMCSA alcohol testing procedures—Overview
- § 7:32 —Requirements
- § 7:33 —Evidential breath testing device
- § 7:34 —Breath Alcohol Technician
- § 7:35 —Alcohol testing site
- § 7:36 —Alcohol testing process
- § 7:37 —EBT screening test
- § 7:38 —ASD screening test

TABLE OF CONTENTS

- § 7:39 —Confirmation test
- § 7:40 —Reporting
- § 7:41 —Incomplete tests
- § 7:42 —Test accuracy
- § 7:43 —Substance abuse professional
- § 7:44 —Alcohol-related conduct
- § 7:45 —Dry run of the program

IV. PRE-EMPLOYMENT TESTING

- § 7:46 Pre-employment alcohol testing
- § 7:47 Refusal to take a DOT alcohol test

V. DOT-AUTHORIZED TECHNICIANS

- § 7:48 DOT alcohol test technicians

VI. ALCOHOL TESTING METHODS

- § 7:49 Field sobriety testing
- § 7:50 Horizontal Gaze Nystagmus (HGN) testing
- § 7:51 Alcohol testing devices, proper administration and use as evidence
- § 7:52 Ignition Interlock Devices (IIDs)
- § 7:53 Breath testing devices—ASD and EBT
- § 7:54 Alcohol Screening Devices (ADS)
- § 7:55 Evidentiary Breath Testing devices (EBT)
- § 7:56 Alcohol test calibrating units
- § 7:57 Breathalyzer
- § 7:58 Theory and operation of breathalyzer
- § 7:59 Infrared testing devices
- § 7:60 Alcotest
- § 7:61 Intoximeters
- § 7:62 Gas chromatography
- § 7:63 Blood testing
- § 7:64 Urine alcohol test
- § 7:65 Saliva alcohol test

VII. TECHNICAL AND POLICY ISSUES

- § 7:66 Technical and policy issues—Custody and control forms
- § 7:67 —Importance of calibration checks and required documentation
- § 7:68 —Law enforcement officers serving as BATs
- § 7:69 —Acetone and alcohol testing
- § 7:70 —Driver alcohol detection system for safety
- § 7:71 —Documentation required for post-accident test delays
- § 7:72 Impaired driving studies

VIII. ALCOHOLISM IN THE WORKPLACE

- § 7:73 Alcoholism in the workplace—In general
- § 7:74 —Employee Assistance Programs (EAPs)
- § 7:75 —Providing help to employee

CHAPTER 8. NONEMPLOYMENT APPLICATIONS FOR ALCOHOL AND DRUG TESTING

- § 8:1 Introduction

I. SCHOOLS

- § 8:2 Drug testing of students
- § 8:3 Amicus Brief in Supreme Court student drug testing case *Board of Education v. Earls*
- § 8:4 Student drug testing under state law
- § 8:5 Implementing a school drug testing program
- § 8:6 —School policy
- § 8:7 —Statement of need
- § 8:8 —Substance abuse program coordinator
- § 8:9 Reasonable suspicion and random testing
- § 8:10 Drug testing is a two-step process
- § 8:11 Specimen collection
- § 8:12 Cutoff levels
- § 8:13 Medical review officer (MRO)
- § 8:14 Confirmation of tests
- § 8:15 Student assistance programs (SAPs)
- § 8:16 —Community involvement in SAPs
- § 8:17 Small schools
- § 8:18 Confidentiality
- § 8:19 —Schools and federal alcohol and drug confidentiality regulations
- § 8:20 —Family Educational Rights and Privacy Act
- § 8:21 —SAPs and confidentiality
- § 8:22 Training
- § 8:23 Model school drug testing policy provisions
- § 8:24 On-site testing for schools
- § 8:25 —Model student random drug testing legislation
- § 8:26 Studies on the effectiveness of student random drug testing

II. CRIMINAL JUSTICE SYSTEM

- § 8:27 Use and admissibility of drug tests
- § 8:28 —Pretrial
- § 8:29 —Drug and alcohol testing of pretrial detainees

TABLE OF CONTENTS

- § 8:30 —Probation and parole
- § 8:31 —Prisoners
- § 8:32 —On-site testing
- § 8:33 Drug courts and on-site drug testing
- § 8:34 Other criminal justice uses of drug and alcohol testing
- § 8:35 Drug testing in federal prisons

III. OTHER NONEMPLOYMENT APPLICATIONS

- § 8:36 Drug-exposed infants and pregnant women
- § 8:37 Drug testing and state drugged driving laws
- § 8:38 Animal testing
- § 8:39 Child custody and child abuse
- § 8:40 Professional licensing and monitoring
- § 8:41 Drug tests for recipients of public assistance
- § 8:42 Drug testing in athletics—National collegiate athletic association (NCAA)
- § 8:43 Steroids testing
- § 8:44 Drug testing and the federal-state unemployment compensation program
- § 8:45 Drug testing in Addiction Medicine

APPENDICES

- APPENDIX A. Governmentwide Requirements for Drug-Free Workplaces for Federal Contractors and Grantees
- APPENDIX B-1. Federal Drug Testing Custody and Control Forms-HHS
- APPENDIX B-2. Mandatory Guidelines for Federal Workplace Drug Testing Programs
- APPENDIX B-2.10. Mandatory Guidelines for Federal Workplace Drug Testing Programs, 82 FR 7920-01, 2017 WL 264702 (January 23, 2017)

Volume 3

- APPENDIX B-2.20. U.S. Department of Health and Human Service Mandatory Guidelines for Federal Workplace Drug Testing Programs—Oral/Fluid
- APPENDIX B-2.30. Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG) with revised standards and technical requirements with an effective date of February 1, 2024

DRUG TESTING LAW TECHNOLOGY AND PRACTICE

- APPENDIX B-2.40. Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG) with revised standards and technical requirements with an effective date of October 10, 2023
- APPENDIX B-2.50. Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, May 1, 2024
- APPENDIX B-3. DOT—Federal Aviation Administration—Drug Testing Program (14 C.F.R. Part 121, App I)
- APPENDIX B-4. DOT—Coast Guard—Chemical Testing (46 C.F.R. Part 16 and § 4.06-60)
- APPENDIX B-5. DOT—Research and Special Programs Administration—Pipeline Safety—Drug and Alcohol Testing (49 C.F.R. Part 199)
- APPENDIX B-6. DOT—Federal Motor Carrier Safety Administration—Controlled Substances and Alcohol Use and Testing (49 C.F.R. Part 382)
- APPENDIX B-7. DOT—Federal Transit Administration—Prevention of Alcohol Misuse and Drug Use in Transit Operations
- APPENDIX B-8. Nuclear Regulatory Commission—Fitness for Duty Programs
- APPENDIX B-9. U.S. Department of Transportation Final Rule—Oral Fluid Testing
- APPENDIX B-10. DOT—Federal Highway Administration—Commercial Driver’s License Standards; Driver Disqualifications and Penalties
- APPENDIX B-11. Cutoff Concentrations for Oral Fluid Drug Tests
- APPENDIX B-12. Office of Personnel Management—Federal Personnel Manual Letter 792-19, Establishing a Drug-Free Federal Workplace (54 Fed Reg 47324)
- APPENDIX B-13. 49 CFR Part 40, Procedures for Transportation Workplace Drug and Alcohol Testing Programs
- APPENDIX B-13.10. Procedures For Transportation Workplace And

TABLE OF CONTENTS

	Alcohol Testing Programs: Drug And Alcohol Management Information System Reporting
APPENDIX B-13.20.	Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Addition of Certain Schedule II Drugs to the Department of Transportation’s Drug-Testing Panel and Certain Minor Amendments, 2017 WL 5236314 (November 13, 2017)
APPENDIX B-14.	Substance Abuse Professional Guidelines
APPENDIX B-15.	<i>[Reserved]</i>
APPENDIX B-16.	Department of Defense—Drug-Free Workplace Rules (48 C.F.R. § 223.570 et seq.)
APPENDIX B-17.	42 CFR Part 2, Confidentiality of Substance Use Disorder Patient Records
APPENDIX B-18.	Highway Safety Programs; Conforming Products List of Screening Devices To Measure Alcohol in Bodily Fluids (June 12, 2012)
APPENDIX B-19.	Federal Department of Transportation Random Testing Rates
APPENDIX B-20.	Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs
APPENDIX B-20.10.	MRO Case Studies Oral Fluid-2024
APPENDIX B-20.20.	MRO Case Studies Urine-2024
APPENDIX B-21.	Highway Safety Programs; Conforming Products List of Evidential Breath Alcohol Measurement Devices, November 2, 2017
APPENDIX B-22.	Highway Safety Programs; Conforming Products List of Calibrating Units for Breath Alcohol Testers (October 22, 2012)
APPENDIX B-23.	DOT—Alcohol Testing Form
APPENDIX B-24.	Title 10 Part 707. Workplace Substance Abuse Programs At DOE Sites
APPENDIX B-25.	DOT Guidance for Employers to Monitor Collection Services
APPENDIX B-26.	Urine Specimen Collection Handbook for Federal Agency Workplace Drug Testing Programs. Revised January, 2022
APPENDIX B-27.	Department of Transportation (DOT)

DRUG TESTING LAW TECHNOLOGY AND PRACTICE

	directly observed urine collection procedures
APPENDIX B-28.	HHS Guidance on Using the 2020 Federal Custody and Control Form for Urine Specimens
APPENDIX B-29.	Model Specifications for Breath Alcohol Ignition Interlock Devices (BAIIDs)
APPENDIX C.	Workplace Drug Testing in the Era of Legal Marijuana
APPENDIX C-1.	NJ Wire Guidance
APPENDIX D.	SAMHSA Opioid Overdose Prevention Toolkit
APPENDIX E.	The Federal Drug-Free Workplace Act
APPENDIX E-1.	Omnibus Transportation Employee Testing Act of 1991
APPENDIX F.	<i>[Reserved]</i>
APPENDIX G.	<i>[Reserved]</i>
APPENDIX H-1.	State Laws That Regulate Drug and Alcohol Use Testing—Alabama
APPENDIX H-2.	State Laws That Regulate Drug and Alcohol Use Testing—Alaska
APPENDIX H-3.	State Laws That Regulate Drug and Alcohol Use Testing—Arizona
APPENDIX H-4.	State Laws That Regulate Drug and Alcohol Use Testing—Arkansas
APPENDIX H-5.	State Laws That Regulate Drug and Alcohol Use Testing—California
APPENDIX H-6.	State Laws That Regulate Drug and Alcohol Use Testing—Colorado <i>[Reserved]</i>
APPENDIX H-7.	State Laws That Regulate Drug and Alcohol Use Testing—Connecticut
APPENDIX H-8.	State Laws That Regulate Drug and Alcohol Use Testing—Delaware
APPENDIX H-9.	State Laws That Regulate Drug and Alcohol Use Testing—District of Columbia
APPENDIX H-10.	State Laws That Regulate Drug and Alcohol Use Testing—Florida
APPENDIX H-11.	State Laws That Regulate Drug and Alcohol Use Testing—Georgia
APPENDIX H-12.	State Laws That Regulate Drug and Alcohol Use Testing—Hawaii

TABLE OF CONTENTS

APPENDIX H-13.	State Laws That Regulate Drug and Alcohol Use Testing—Idaho
APPENDIX H-14.	State Laws That Regulate Drug and Alcohol Use Testing—Illinois
APPENDIX H-15.	State Laws That Regulate Drug and Alcohol Use Testing—Indiana
APPENDIX H-16.	State Laws That Regulate Drug and Alcohol Use Testing—Iowa
APPENDIX H-17.	State Laws That Regulate Drug and Alcohol Use Testing—Kansas
APPENDIX H-18.	State Laws That Regulate Drug and Alcohol Use Testing—Kentucky
APPENDIX H-19.	State Laws That Regulate Drug and Alcohol Use Testing—Louisiana
APPENDIX H-20.	State Laws That Regulate Drug and Alcohol Use Testing—Maine
APPENDIX H-21.	State Laws That Regulate Drug and Alcohol Use Testing—Maryland
APPENDIX H-22.	State Laws That Regulate Drug and Alcohol Use Testing—Massachusetts <i>[Reserved]</i>
APPENDIX H-23.	State Laws That Regulate Drug and Alcohol Use Testing—Michigan
APPENDIX H-24.	State Laws That Regulate Drug and Alcohol Use Testing—Minnesota
APPENDIX H-25.	State Laws That Regulate Drug and Alcohol Use Testing—Mississippi
APPENDIX H-26.	State Laws That Regulate Drug and Alcohol Use Testing—Missouri
APPENDIX H-27.	State Laws That Regulate Drug and Alcohol Use Testing—Montana
APPENDIX H-28.	State Laws That Regulate Drug and Alcohol Use Testing—Nebraska
APPENDIX H-29.	State Laws That Regulate Drug and Alcohol Use Testing—Nevada
APPENDIX H-30.	State Laws That Regulate Drug and Alcohol Use Testing—New Hampshire <i>[Reserved]</i>
APPENDIX H-31.	State Laws That Regulate Drug and Alcohol Use Testing—New Jersey <i>[Reserved]</i>
APPENDIX H-32.	State Laws That Regulate Drug and Alcohol Use Testing—New Mexico <i>[Reserved]</i>
APPENDIX H-33.	State Laws That Regulate Drug and Alcohol Use Testing—New York <i>[Reserved]</i>
APPENDIX H-34.	State Laws That Regulate Drug and Alcohol Use Testing—North Carolina

DRUG TESTING LAW TECHNOLOGY AND PRACTICE

- APPENDIX H-35. State Laws That Regulate Drug and Alcohol Use Testing—North Dakota
- APPENDIX H-36. State Laws That Regulate Drug and Alcohol Use Testing—Ohio
- APPENDIX H-37. State Laws That Regulate Drug and Alcohol Use Testing—Oklahoma
- APPENDIX H-38. State Laws That Regulate Drug and Alcohol Use Testing—Oregon
- APPENDIX H-39. State Laws That Regulate Drug and Alcohol Use Testing—Pennsylvania *[Reserved]*
- APPENDIX H-40. State Laws That Regulate Drug and Alcohol Use Testing—Puerto Rico
- APPENDIX H-41. State Laws That Regulate Drug and Alcohol Use Testing—Rhode Island
- APPENDIX H-42. State Laws That Regulate Drug and Alcohol Use Testing—South Carolina
- APPENDIX H-43. State Laws That Regulate Drug and Alcohol Use Testing—South Dakota
- APPENDIX H-44. State Laws That Regulate Drug and Alcohol Use Testing—Tennessee
- APPENDIX H-45. State Laws That Regulate Drug and Alcohol Use Testing—Texas
- APPENDIX H-46. State Laws That Regulate Drug and Alcohol Use Testing—Utah
- APPENDIX H-47. State Laws That Regulate Drug and Alcohol Use Testing—Vermont
- APPENDIX H-48. State Laws That Regulate Drug and Alcohol Use Testing—Virginia *[Reserved]*
- APPENDIX H-49. State Laws That Regulate Drug and Alcohol Use Testing—Virgin Islands *[Reserved]*
- APPENDIX H-50. State Laws That Regulate Drug and Alcohol Use Testing—Washington *[Reserved]*
- APPENDIX H-51. State Laws That Regulate Drug and Alcohol Use Testing—West Virginia
- APPENDIX H-52. State Laws That Regulate Drug and Alcohol Use Testing—Wisconsin
- APPENDIX H-53. State Laws That Regulate Drug and Alcohol Use Testing—Wyoming *[Reserved]*
- APPENDIX I. Forms
- APPENDIX I-1. Consent to Drug Test under Federal Regulations
- APPENDIX I-2. Recording Prescription Medicine Form

TABLE OF CONTENTS

APPENDIX I-3.	Authorization for Release of Medical Information
APPENDIX I-4.	Alcohol/Drug Patient Records Release Authorization
APPENDIX I-5.	Label for Specimen Container and Lid
APPENDIX I-6.	Chain of Custody Form
APPENDIX I-7.	Chain of Custody Form for On-Site Testing
APPENDIX I-8.	Reasonable Suspicion Report
APPENDIX I-9.	Drug/Alcohol Test Results Form
APPENDIX I-10.	Annual Drug Testing Data Summary
APPENDIX I-11.	Qualified Service Organization Agreement for a Laboratory
APPENDIX I-12.	Liability Release Waiver
APPENDIX I-13.	Liability Release—Indemnity
APPENDIX I-14.	Equipment Validation and Operator Qualification Form
APPENDIX I-15.	Training Certification
APPENDIX I-16.	On-Site Drug Test Results—Negative Test Certification Form
APPENDIX I-17.	On-Site Drug Test Results—On-Site Drug Test Result Form
APPENDIX I-18.	Last Chance Agreement Form
APPENDIX J. <i>[Reserved]</i>	
APPENDIX J-1.	NDASA: CBD and Drug Testing
APPENDIX J-2.	NDASA: Recommended Safe Practices and Procedures During COVID-19
APPENDIX J-3.	NDASA: Marijuana and Workplace Policies
APPENDIX J-4.	NDASA: How COVID-19 Affects our Industry
APPENDIX K. <i>[Reserved]</i>	
APPENDIX L.	Federal Conditions of Release Drug Testing Requirements

Table of Laws and Rules

Table of Cases

Index